|
1
|
Paul S and Dey A: Wnt signaling and cancer
development: therapeutic implication. Neoplasma. 55:165–176.
2008.PubMed/NCBI
|
|
2
|
Prosperi JR and Goss KH: A Wnt-ow of
opportunity: targeting the Wnt/beta-catenin pathway in breast
cancer. Curr Drug Targets. 11:1074–1088. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miller JR: The Wnts. Genome Biol. 3:1–15.
2002.
|
|
4
|
Polakis P: Wnt signaling and cancer. Genes
Dev. 14:1837–1851. 2000.
|
|
5
|
Lustig B and Behrens J: The Wnt signaling
pathway and its role in tumor development. J Cancer Res Clin Oncol.
129:199–221. 2003.PubMed/NCBI
|
|
6
|
Van Aken E, De Wever O, Correia da Rocha
AS and Mareel M: Defective E-cadherin/catenin complexes in human
cancer. Virchows Arch. 439:725–751. 2001.PubMed/NCBI
|
|
7
|
Luo W and Lin SC: Axin: a master scaffold
for multiple signaling pathways. Neurosignals. 13:99–113. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Böcker W: WHO classification of breast
tumors and tumors of the female genital organs: pathology and
genetics. Verh Dtsch Ges Pathol. 86:116–119. 2002.(In German).
|
|
9
|
Maruyama K, Ochiai A, Akimoto S, et al:
Cytoplasmic beta-catenin as a predictor of hematogenous metastasis
in human colorectal cancer. Oncology. 59:302–309. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakajima M, Fukuchi M, Miyazaki T, et al:
Reduced expression of Axin correlates with tumour progression of
oesophageal squamous cell carcinoma. Br J Cancer. 88:1734–1739.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bankfalvi A, Terpe HJ, Breukelmann D, et
al: Immunophenotypic and prognostic analysis of E-cadherin and
beta-catenin expression during breast carcinogenesis and tumour
progression: a comparative study with CD44. Histopathology.
34:25–34. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin SY, Xia W, Wang JC, et al:
Beta-catenin, a novel prognostic marker for breast cancer: its
roles in cyclin D1 expression and cancer progression. Proc Natl
Acad Sci USA. 97:4262–4266. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lim SC and Lee MS: Significance of
E-cadherin/beta-catenin complex and cyclin D1 in breast cancer.
Oncol Rep. 9:915–928. 2002.PubMed/NCBI
|
|
14
|
Dolled-Filhart M, McCabe A, Giltnane J, et
al: Quantitative in situ analysis of beta-catenin expression in
breast cancer shows decreased expression is associated with poor
outcome. Cancer Res. 66:5487–5494. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
López-Knowles E, Zardawi SJ, McNeil CM, et
al: Cytoplasmic localization of beta-catenin is a marker of poor
outcome in breast cancer patients. Cancer Epidemiol Biomarkers
Prev. 19:301–309. 2010.PubMed/NCBI
|
|
16
|
Chung GG, Zerkowski MP, Ocal IT, et al:
beta-Catenin and p53 analyses of a breast carcinoma tissue
microarray. Cancer. 100:2084–2092. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Z, Ren Y, He JJ, et al: Relationship
between ectopic expression of Wnt/beta-catenin signaling pathway
and Her-2 overexpression in human breast carcinoma. J Xi’an
Jiaotong Univ (Med Sci). 30:587–591. 2009.
|
|
18
|
Kikuchi A: Tumor formation by genetic
mutations in the components of the Wnt signaling pathway. Cancer
Sci. 94:225–229. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He YJ, Jia XS, Qing SKZ, et al: The study
on p53 and beta-catenin gene mutations in NK/T cell lymphoma. Chin
J Clin Oncol. 31:1385–1388. 2004.
|
|
20
|
Zhuang SM, Wiseman RW and Söderkvist P:
Frequent mutations of the Trp53, Hras1 and beta-catenin (Catnb)
genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1
mice. Oncogene. 21:5643–5648. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Howe LR and Brown AM: Wnt signaling and
breast cancer. Cancer Biol Ther. 3:36–41. 2004. View Article : Google Scholar
|
|
22
|
Ozaki S, Ikeda S, Ishizaki Y, et al:
Alterations and correlations of the components in the Wnt signaling
pathway and its target genes in breast cancer. Oncol Rep.
14:1437–1443. 2005.PubMed/NCBI
|
|
23
|
Kizildag S, Zengel B, Vardar E, et al:
beta-catenin gene mutation in invasive ductal breast cancer. J
BUON. 13:533–536. 2008.PubMed/NCBI
|
|
24
|
Abraham SC, Rcynolds C, Lee JH, et al:
Fibromatosis of the breast and mutations involving the
APC/beta-catenin pathway. Hum Pathol. 33:39–46. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zeng L, Fagotto F, Zhang T, et al: The
mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling
pathway that regulates embryonic axis formation. Cell. 90:181–192.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu HT, Wang L, Lin D, et al: Abnormal
beta-catenin and reduced axin expression are associated with poor
differentiation and progression in non-small cell lung cancer. Am J
Clin Pathol. 125:534–541. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ishizaki Y, Ikeda S, Fujimori M, et al:
Immunohistochemical analysis and mutational analyses of
beta-catenin, Axin family and APC genes in hepatocellular
carcinomas. Int J Oncol. 24:1077–1083. 2004.PubMed/NCBI
|
|
28
|
Jin LH, Shao QJ, Luo W, et al: Detection
of point mutations of the Axin1 gene in colorectal cancers. Int J
Cancer. 107:696–699. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cong F and Varmus H: Nuclear-cytoplasmic
shuttling of Axin regulates subcellular localization of
beta-catenin. Proc Natl Acad Sci USA. 101:2882–2887. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cliffe A, Hamada F and Bienz M: A role of
Dishevelled in relocating Axin to the plasma membrane during
wingless signaling. Curr Biol. 13:960–966. 2003. View Article : Google Scholar
|
|
31
|
Roh MS, Hong SH, Jeong JS, et al: Gene
expression profiling of breast cancer with emphasis of beta-catenin
regulation. J Korean Med Sci. 19:275–282. 2004. View Article : Google Scholar : PubMed/NCBI
|
